Literature DB >> 9039114

Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension.

S Taddei1, A Virdis, L Ghiadoni, A Magagna, A Salvetti.   

Abstract

To evaluate whether cyclooxygenase constrictor substances can impair nitric oxide-mediated vasodilation in essential hypertension, in seven normotensive subjects (43.3 +/- 4.1 years; BP, 117 +/- 6/81 +/- 2 mm Hg) and seven essential hypertensive patients (47.1 +/- 5.2 years; BP, 151 +/- 8/98 +/- 4 mm Hg) we studied forearm blood flow (strain-gauge plethysmography) modifications induced by intrabrachial acetylcholine (0.15, 0.45, 1.5, 4.5, 15 micrograms.100 mL-1.min-1) in basal conditions, during infusion of NG-monomethyl-L-arginine (L-NMMA; 100 micrograms.100 mL-1.min-1), a nitirc oxide synthase inhibitor, or indomethacin (50 micrograms.100 mL-1.min-1), a cyclooxygenase inhibitor, or simultaneous indomethacin and L-NMMA. In normotensives, vasodilation to acetylcholine was blunted by L-NMMA (maximum flow increase: 671 +/- 64% and 386 +/- 42%, respectively; P < .01), and this effect was unchanged by indomethacin. In contrast, in hypertensive patients, vasodilation to acetylcholine (maximum flow increase: 458 +/- 33%) was unchanged by L-NMMA. Indomethacin significantly (P < .01) increased the response to acetylcholine (maximum flow increase: 635 +/- 53%) and restored the inhibitory effect of L-NMMA (maximum flow increase: 445 +/- 36%; P < .01 versus indomethacin alone). In an adjunctive seven normotensives (51.4 +/- 4.2 years; BP, 114 +/- 5/79 +/- 3 mm Hg) and seven essential hypertensives (53.2 +/- 7.6 years; BP, 153 +/- 9/100 +/- 3 mm Hg) we repeated the same protocol by replacing L-NMMA with L-arginine (200 micrograms.100 mL-1.min-1), the substrate for NO synthase. In normotensives, vasodilation to acetylcholine was increased by L-arginine (maximum flow increase: 539 +/- 48% and 806 +/- 61%, respectively) and this effect was unchanged by indomethacin. In hypertensive patients, vasodilation to acetylcholine (maximum flow increase: 339 +/- 32%) was unchanged by L-arginine but was significantly (P < .01) increased by indomethacin (maximum flow increase: 592 +/- 38%). Moreover, indomethacin restored the facilitatory effect of L-arginine (maximum flow increase: 804 +/- 56%; P < .01 versus indomethacin alone). Therefore, cyclooxygenase inhibition restores nitric oxide-mediated vasodilation in essential hypertension, suggesting that cyclooxygenase-dependent substances can impair nitric oxide production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039114     DOI: 10.1161/01.hyp.29.1.274

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  38 in total

Review 1.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Vasoconstrictor prostanoids.

Authors:  Michel Félétou; Yu Huang; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-03-24       Impact factor: 3.657

3.  Role of nitric oxide and prostanoids in the regulation of leg blood flow and blood pressure in humans with essential hypertension: effect of high-intensity aerobic training.

Authors:  Michael Nyberg; Lasse G Jensen; Pia Thaning; Ylva Hellsten; Stefan P Mortensen
Journal:  J Physiol       Date:  2012-01-23       Impact factor: 5.182

Review 4.  Essential Hypertension and Functional Microvascular Ageing.

Authors:  Rosa Maria Bruno; Stefano Masi; Marco Taddei; Stefano Taddei; Agostino Virdis
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-01-09

Review 5.  Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Authors:  Irmgard Tegeder; Gerd Geisslinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-04       Impact factor: 3.000

Review 6.  Nitric oxide in the human cardiovascular system--SKB lecture 1997.

Authors:  P Vallance
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

7.  Reversible suppression of nitric oxide system in essential hypertension.

Authors:  M Chandra; D R Maurya; S Kumar; H Basara; A Ghatak; B L Tekwani; G Kaur; M K Misra
Journal:  Indian J Clin Biochem       Date:  2003-07

Review 8.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

Review 9.  Endothelium-dependent contractions: when a good guy turns bad!

Authors:  Paul M Vanhoutte; Eva H C Tang
Journal:  J Physiol       Date:  2008-09-25       Impact factor: 5.182

Review 10.  Alzheimer's disease and endothelial dysfunction.

Authors:  Giuseppe Bomboi; Lorenzo Castello; Francesco Cosentino; Franco Giubilei; Francesco Orzi; Massimo Volpe
Journal:  Neurol Sci       Date:  2009-10-17       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.